by Stephen Manobiano | Oct 7, 2026 | Automation, Commercialization, CRM best practices, Data Management, Founders and Business Leaders, HubSpot, Insight
12 Questions Life Science Founders, CEOs, and Commercial Leaders Ask When Choosing a CRM for a Product or Service Company Most “best life sciences CRM” lists are written for global pharma: field forces calling on physicians, regulated sample distribution, and...
by Stephen Manobiano | Oct 7, 2026 | AI, Commercialization, Founders and Business Leaders, Insight, Marketing, Private Equity, Sales, Venture Capital
13 Questions PE Operating Partners Ask About Commercial Value Creation in Life Science Tools, CRO/CDMO, and Diagnostics Portfolio Companies Private equity has become one of the most active sources of capital in life science tools, reagents, CRO/CDMO services, genomics...
by Stephen Manobiano | Sep 15, 2026 | Commercialization, Founders and Business Leaders, Insight
How founders of reagent, kit, assay, instrument, and software tool companies use commercial strategy to raise their next round and reach first revenue faster. Most biotech tool companies are founded on a genuine technical advance: a more sensitive assay, a cleaner...
by Matthew Manobianco | Sep 10, 2026 | Commercialization, CRM best practices, HubSpot, news
Choosing a CRM is only the first step. The more important question is whether the system will be designed, implemented, and managed around the way your life sciences company actually operates. Biotech companies, CROs, CDMOs, research-tool manufacturers, reagent...
by Stephen Manobiano | Aug 25, 2026 | business development, Commercialization, Founders and Business Leaders, Insight, Marketing, Sales
Why referrals and customer mobility, not brand marketing alone, drive new-account growth in life science markets, and how to build the ask into your sales playbook, battle cards, and CRM automation. When I led commercial efforts at GENEWIZ, we made a deliberate bet:...
by Stephen Manobiano | Jul 1, 2026 | business development, Commercialization, CRM best practices, Data Management, Founders and Business Leaders, Fractional, Marketing, news, Sales
NGS isn’t “next gen” anymore. The core sequencing instrument market is dominated by a small number of established platform vendors, and that’s not changing. If your growth strategy still depends on competing for that instrument-level attention, you’re...
